Switch theme
Sign up to access all valuation multiples
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
2003
2.8K+
LTM Revenue $4.1B
LTM EBITDA $1.9B
$9.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jazz Pharmaceuticals has a last 12-month revenue of $4.1B and a last 12-month EBITDA of $1.9B.
In the most recent fiscal year, Jazz Pharmaceuticals achieved revenue of $4.1B and an EBITDA of $1.4B.
Jazz Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jazz Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $4.1B | XXX | XXX | XXX |
| Gross Profit | $3.1B | $3.4B | XXX | XXX | XXX |
| Gross Margin | 81% | 84% | XXX | XXX | XXX |
| EBITDA | $1.2B | $1.4B | XXX | XXX | XXX |
| EBITDA Margin | 32% | 34% | XXX | XXX | XXX |
| Net Profit | -$224M | $415M | XXX | XXX | XXX |
| Net Margin | -6% | 10% | XXX | XXX | XXX |
| Net Debt | $4.8B | $4.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jazz Pharmaceuticals's stock price is $102.
Jazz Pharmaceuticals has current market cap of $6.2B, and EV of $9.3B.
See Jazz Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.3B | $6.2B | XXX | XXX | XXX | XXX | $21.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jazz Pharmaceuticals has market cap of $6.2B and EV of $9.3B.
Jazz Pharmaceuticals's trades at 2.3x LTM EV/Revenue multiple, and 4.9x LTM EBITDA.
Analysts estimate Jazz Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jazz Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.3B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | XXX | XXX |
| P/E | 11.0x | XXX | XXX | XXX |
| P/E/Growth | 0.2x | XXX | XXX | XXX |
| EV/FCF | 6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJazz Pharmaceuticals's NTM/LTM revenue growth is 5%
Jazz Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.5M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Jazz Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jazz Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jazz Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 38% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 71% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jazz Pharmaceuticals acquired XXX companies to date.
Last acquisition by Jazz Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Jazz Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jazz Pharmaceuticals founded? | Jazz Pharmaceuticals was founded in 2003. |
| Where is Jazz Pharmaceuticals headquartered? | Jazz Pharmaceuticals is headquartered in United States of America. |
| How many employees does Jazz Pharmaceuticals have? | As of today, Jazz Pharmaceuticals has 2.8K+ employees. |
| Who is the CEO of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's CEO is Mr. Bruce C. Cozadd. |
| Is Jazz Pharmaceuticals publicy listed? | Yes, Jazz Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Jazz Pharmaceuticals? | Jazz Pharmaceuticals trades under JAZZ ticker. |
| When did Jazz Pharmaceuticals go public? | Jazz Pharmaceuticals went public in 2007. |
| Who are competitors of Jazz Pharmaceuticals? | Similar companies to Jazz Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's current market cap is $6.2B |
| What is the current revenue of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's last 12-month revenue is $4.1B. |
| What is the current EBITDA of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's last 12-month EBITDA is $1.9B. |
| What is the current EV/Revenue multiple of Jazz Pharmaceuticals? | Current revenue multiple of Jazz Pharmaceuticals is 2.3x. |
| What is the current EV/EBITDA multiple of Jazz Pharmaceuticals? | Current EBITDA multiple of Jazz Pharmaceuticals is 4.9x. |
| What is the current revenue growth of Jazz Pharmaceuticals? | Jazz Pharmaceuticals revenue growth between 2023 and 2024 was 6%. |
| Is Jazz Pharmaceuticals profitable? | Yes, Jazz Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
